Novo Nordisk enters collaboration with Heartseed on cell-based treatment
Through the new agreement, Novo Nordisk gets exclusive rights to develop, produce and market Heartseed's HS-001 product for the treatment of cardiovascular diseases all over the world, excluding Japan.
BY RITZAU FINANS, TRANSLATED BY CATHERINE BRETT
Novo Nordisk and Heartseed have entered an exclusive global partnership and license agreement over the development, production and marketing of Heartseed's HS-001 to treat cardiovascular diseases, Novo Nordisk reports in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
